Knowledge is power when living with IBD.
Get access to the web’s leading IBD news & insights for as little as 16¢/day.Already a subscriber? Sign in here
New Data Show Kappaproct’s Potential in Treating Ulcerative Colitis
Based on newly available data, researchers better understand how the Toll-like receptor 9 (TLR9) agonist Kappaproct (cobitolimod), developed by InDex Pharmaceuticals, can provide anti-inflammatory relief of the clinical symptoms of ulcerative colitis (UC). The research shows how Kappaproct regulates two specialized types of immune cells — T helper 17 (Th17) and T regulatory (Treg) — in test animals